GLP-1 Drugs and Aging: What the Evidence So Far Suggests
Graded Preliminary — a review summarising existing animal, lab and patient studies; trials designed to measure biological age as their main goal have not yet been done.
- Design
- Narrative review
- Participants
- N/A
- Duration
- —
- Funding
- —
In one trial, three epigenetic clocks that estimate biological age ran more slowly over 32 weeks of semaglutide.
Drugs such as semaglutide mimic the gut hormone GLP-1 and are widely known as weight-loss jabs. In trials where chance decided who got the drug, they cut serious heart and blood vessel disease, deaths and inflammation in the blood. The benefits were larger than better blood sugar and weight loss alone would predict. A review now asks whether these drugs might slow aging itself.
The authors pull together animal, lab and patient studies. In the SELECT trial, people with obesity but no diabetes had a 19 percent lower risk of dying. In 2025, the first trial with random assignment looked at epigenetic clocks. These estimate biological age from chemical tags on DNA. On semaglutide, three such clocks ticked more slowly over 32 weeks. As possible routes, the authors point to signals in the brain, an energy sensor inside cells and substances made by gut bacteria.
The authors call the drugs candidates, not proven anti-aging treatments. Trials that measure biological age as a main goal from the start, with long follow-up, are still missing. It is also open how much muscle people lose on the drugs and whether women and men respond alike.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.